Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Restructuring Costs for 2 consecutive years, with $2.1 million as the latest value for Q3 2024.

  • On a quarterly basis, Restructuring Costs changed N/A to $2.1 million in Q3 2024 year-over-year; TTM through Dec 2025 was $2.1 million, a 1.88% increase, with the full-year FY2024 number at $2.1 million, changed N/A from a year prior.
  • Restructuring Costs was $2.1 million for Q3 2024 at Fulcrum Therapeutics, up from -$38000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $2.1 million in Q3 2024 to a low of -$38000.0 in Q4 2022.